Health

Here’s the breakdown on what’s really driving America’s runaway drug prices — and whether any of the current plans stand a chance to lower your pharmacy bill.

Phillip Alvelda, a former DARPA program manager, reveals how a fracturing federal system has opened the door for bold state leadership. Will blue states rise to build a healthier, more just future?

Has the Inflation Reduction Act hindered pharmaceutical innovation? Evidence shows that the pharma industry can strategically manage disruptive change.

Misaligned incentives account for many of the most troubling features of the pharmaceutical industry’s present practices and performance.

Phillip Alvelda, a scientist and entrepreneur with past roles at NASA and DARPA, sounds the alarm on cuts that threaten the innovative capacities that have made America a global powerhouse.

The country’s flawed insurance model, driven by greed, leads to inefficiency, inequality, and denied care - a colossal scam that has sparked fury across the nation.

Dr. Victor Gurewich, a researcher and Harvard Medical School faculty member since 1965, discovered a breakthrough drug treatment for heart attacks and strokes with the potential to save millions, but institutional resistance and a U.S. healthcare system that puts profits over patients are keeping it out of reach.

Medicare negotiators need to have a deep understanding - both theoretical and empirical - of the learning processes involved in developing a drug to negotiate a price that is fair.

Medicare Needs a Perspective on “Collective and Cumulative Learning” in Inflation Reduction Act Negotiations

The IRA has the potential to rectify the imbalance between public benefit and private incentives

Increasing evidence that the IRA is probably not harming pharmaceutical innovation.

Sensitivity of investment and valuation to drug price indices and market conditions

Dr. Phillip Alvelda tells INET’s Lynn Parramore about persistent political and public health failures exposing us to devastating diseases, while vastly underestimating their long-term health effects.

In a candid discussion with INET’s Lynn Parramore, Dr. Phillip Alvelda highlights the imminent dangers of long COVID, criticizing governments and health agencies for ongoing preventable suffering and deaths. *This is Part 2 of a two-part interview.

Stuck in a fog of misleading narratives, most of us don’t see the true extent of COVID’s persisting—and intensifying—threats. INET’s Lynn Parramore talks to Dr. Phillip Alvelda about the dangers we’re missing and the failures of public health agencies to inform and protect us. *This is Part 1 of a two-part interview.